Aprea Therapeutics (APRE) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow JonesNov 18 07:51 ET · Ratings
Here's Why Aprea Therapeutics (APRE) Could Be Great Choice for a Bottom Fisher
Yahoo FinanceNov 13 09:55 ET
Express News | Aprea Therapeutics - Got Into at the Market Offering Agreement, May Offer & Sell Shares of Common Stock of up to $3 Mln From Time to Time - SEC Filing
ReutersNov 8 18:04 ET
Buy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial Positioning
TipRanksNov 8 12:45 ET
Aprea Therapeutics | 8-K: Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
SECNov 7 08:43 ET
Aprea Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 7 08:38 ET · Announcements

Comments

Jaguar8

Oct 23 07:33

NEWS

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics (APRE) presented preliminary safety results for its WEE1 inhibitor APR-1051 at the EORTC-NCI-AACR Symposium. The Phase 1 ACESOT-1051 trial is evaluating APR-1051 as monotherapy in advanced solid tumors. Data from two of three enrolled patients show the drug is safe and well-tolerated ...

Stock_Drift

Oct 15 12:43

Unusual Volume Ticks. 1:42pm 10/15

$Wolfspeed (WOLF.US)$ $Wang & Lee Group (WLGS.US)$ $Aprea Therapeutics (APRE.US)$ $Eco Wave Power (WAVE.US)$ $Phunware (PHUN.US)$ $Gritstone Bio (GRTS.US)$ $Aditxt (ADTX.US)$ $Zapata Computing (ZPTA.US)$ $ADVISORSHARES PSYCHEDELICS ETF (PSIL.US)$ $NewGenIvf (NIVF.US)$ $Bright Minds Biosciences (DRUG.US)$

3

1

Jaguar8

Jun 17 07:31

NEWS

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA dam...

Jaguar8

May 28 07:48

NEWS

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics announced that the Safety Review Committee (SRC) has approved dosing patients with ATRN-119 at 800 mg once daily in the ongoing ABOYA-119 clinical trial. ATRN-119, the first macrocyclic ATR inhibitor in clinic trials, has demonstrated a favorable safety profile through five dosage le...

1

Jaguar8

Apr 10 11:11

$Aprea Therapeutics (APRE.US)$
NEWS
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a n...

APRE Aprea Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target